Background
Investors Sandra Hunter and Marla Strappe alleged that Elanco Animal Health and several officers and directors misled the market about demand for Elanco’s products. According to their proposed second amended complaint, Elanco used discounts, rebates, and favorable payment terms to induce distributors to buy inventory beyond end-user demand, while executives publicly attributed the company’s revenue growth to strong underlying demand.
In May 2020, Elanco announced that it had reduced distributor inventory by approximately $60 million and expected a further reduction of $80 million to $100 million, principally in the second quarter. Its stock price fell 13%. The investors asserted claims under the Securities Exchange Act of 1934, the Securities Act of 1933, and Item 303 of Regulation S-K, along with control-person claims. The district court denied leave to file the proposed amended complaint as futile and dismissed the action with prejudice.
The Court’s Holding
The Seventh Circuit affirmed. It rejected the district court’s premise that a Rule 10b-5(b) claim concerning channel stuffing requires the underlying practice itself to be fraudulent. Because Rule 10b-5(b) focuses on false statements and misleading omissions, a statement about an otherwise lawful business strategy can be actionable. Some of Elanco’s specific assurances about underlying demand were close questions, but the court did not decide whether they were materially misleading.
The Exchange Act claim nevertheless failed because the complaint did not create the strong inference of scienter required by the Private Securities Litigation Reform Act. The more compelling inference was that Elanco’s executives pursued a lawful sales strategy they realistically believed was working: the sales were genuine, product returns remained low, the financial statements were never restated, and the complaint did not adequately allege that the executives knew demand was weak or that the strategy was unsustainable.
The Securities Act claims under Sections 11 and 12(a)(2) were governed by Rule 9(b) because they relied on the same allegedly deceptive course of conduct as the fraud claim, despite the complaint’s formal disclaimer of fraud. The investors did not argue that they satisfied Rule 9(b). The Item 303 claim also failed because Elanco’s “move in” model was an internal sales strategy, not the type of external trend or uncertainty Item 303 required it to disclose. With no viable primary violation, the derivative control-person claims under Section 15 of the Securities Act and Section 20(a) of the Exchange Act failed as well.
Key Takeaways
- Rule 10b-5(b) can reach materially misleading statements about a lawful business practice; plaintiffs need not show that the underlying channel stuffing was itself fraudulent.
- Knowledge of high distributor inventory does not alone establish a strong inference of scienter when sales were real, returns stayed low, and the complaint did not show that executives knew demand was weak or the strategy would fail.
- Securities Act claims based on the same alleged deceptive course of conduct as an Exchange Act fraud claim may be subject to Rule 9(b), notwithstanding an express disclaimer of fraud.
Why It Matters
The decision separates statement-based liability under Rule 10b-5(b) from scheme liability: lawful channel stuffing does not insulate a company’s descriptions of demand from scrutiny. But plaintiffs still must plead particularized facts supporting a cogent inference that defendants intended to mislead investors, not merely that executives knew distributors carried substantial inventory.
The opinion also aligns the Seventh Circuit with several other circuits in applying Rule 9(b) when Securities Act and Exchange Act claims arise from the same alleged fraudulent course of conduct. Plaintiffs cannot avoid heightened pleading requirements simply by labeling parallel Securities Act theories as negligence or strict liability.